These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 22926034)

  • 1. Clinical value of drugs targeting inflammation for the management of coronary artery disease.
    Duchatelle V; Kritikou EA; Tardif JC
    Can J Cardiol; 2012; 28(6):678-86. PubMed ID: 22926034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inflammation, C-reactive protein, and atherothrombosis.
    Ridker PM; Silvertown JD
    J Periodontol; 2008 Aug; 79(8 Suppl):1544-51. PubMed ID: 18673009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-inflammatory drugs and atherosclerosis.
    Moubayed SP; Heinonen TM; Tardif JC
    Curr Opin Lipidol; 2007 Dec; 18(6):638-44. PubMed ID: 17993809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treating inflammation in atherosclerotic cardiovascular disease: emerging therapies.
    Klingenberg R; Hansson GK
    Eur Heart J; 2009 Dec; 30(23):2838-44. PubMed ID: 19880848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HMG-CoA reductase inhibition: anti-inflammatory effects beyond lipid lowering?
    März W; Köenig W
    J Cardiovasc Risk; 2003 Jun; 10(3):169-79. PubMed ID: 12775949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toward immunomodulatory and anti-inflammatory properties of statins.
    Arnaud C; Braunersreuther V; Mach F
    Trends Cardiovasc Med; 2005 Aug; 15(6):202-6. PubMed ID: 16182129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The molecular basis of vulnerable plaque: potential therapeutic role for immunomodulation.
    Wilensky RL; Hamamdzic D
    Curr Opin Cardiol; 2007 Nov; 22(6):545-51. PubMed ID: 17921743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipoproteins as biomarkers and therapeutic targets in the setting of acute coronary syndrome.
    Rosenson RS; Brewer HB; Rader DJ
    Circ Res; 2014 Jun; 114(12):1880-9. PubMed ID: 24902972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inflammation in coronary artery diseases.
    Li JJ
    Chin Med J (Engl); 2011 Nov; 124(21):3568-75. PubMed ID: 22340179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. From pathophysiology to targeted therapy for atherothrombosis: a role for the combination of statin and aspirin in secondary prevention.
    Chapman MJ
    Pharmacol Ther; 2007 Jan; 113(1):184-96. PubMed ID: 17070923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Atherosclerosis and arteriitis: implications for therapy of cardiovascular disease].
    Galle J
    Herz; 2004 Feb; 29(1):4-11. PubMed ID: 14968336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytokines, macrophage lipid metabolism and foam cells: implications for cardiovascular disease therapy.
    McLaren JE; Michael DR; Ashlin TG; Ramji DP
    Prog Lipid Res; 2011 Oct; 50(4):331-47. PubMed ID: 21601592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.
    Mohler ER; Ballantyne CM; Davidson MH; Hanefeld M; Ruilope LM; Johnson JL; Zalewski A;
    J Am Coll Cardiol; 2008 Apr; 51(17):1632-41. PubMed ID: 18436114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Does Lp-PLA2 determination help predict atherosclerosis and cardiocerebrovascular disease?].
    Sertić J; Skorić B; Lovrić J; Bozina T; Reiner Z
    Acta Med Croatica; 2010 Oct; 64(4):237-45. PubMed ID: 21688606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inflammation and beyond: new directions and emerging drugs for treating atherosclerosis.
    Bertrand MJ; Tardif JC
    Expert Opin Emerg Drugs; 2017 Mar; 22(1):1-26. PubMed ID: 27927063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statins and other agents for vascular inflammation.
    Owens CD
    J Vasc Surg; 2012 Dec; 56(6):1799-806. PubMed ID: 23017371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new way of targeting to treat coronary artery disease.
    Siu D
    J Cardiovasc Med (Hagerstown); 2010 Jan; 11(1):1-6. PubMed ID: 19829140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ; Yellon DM
    Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the unstable plaque in acute coronary syndromes.
    Thompson PL; Nidorf SM; Eikelboom J
    Clin Ther; 2013 Aug; 35(8):1099-107. PubMed ID: 23973042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of vascular inflammation in coronary artery disease: potential of anti-inflammatory drugs in the prevention of atherothrombosis. Inflammation and anti-inflammatory drugs in coronary artery disease.
    Moreira DM; da Silva RL; Vieira JL; Fattah T; Lueneberg ME; Gottschall CA
    Am J Cardiovasc Drugs; 2015 Feb; 15(1):1-11. PubMed ID: 25369900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.